|
CN104119292A
|
|
Preparation method of dasatinib intermediate
|
|
CN104016949A
|
|
Method for synthesizing 4-amino-5-chloro-2,3-dihydro benzofuran-7-carboxylic acid
|
|
CN103804211A
|
|
Synthetic method of 4-(acetyl amino)-2-hydroxy-3-(2-carbonyl ethyl) methyl benzoate
|
|
CN103804350A
|
|
Method for preparing high-purity pomalidomide
|
|
CN102850290A
|
|
Preparation method of crystal form I linezolid
|
|
CN102617310A
|
|
Adamantane formaldehyde synthetic method suitable for industrial production
|
|
CN102228426A
|
|
21(R) argatroban intravenous injection with alcohol as solubilizer
|
|
CN102228677A
|
|
21 (R) argatroban intravenous injection containing acid as solubiliser
|
|
CN102119922A
|
|
21(S) Argatroban intravenous injection taking acid as solubilizer
|
|
CN102120026A
|
|
21(S) argatroban intravenous injection with alcohol as solubilizer
|
|
CN102060719A
|
|
Method for preparing midodrine hydrochloride intermediate 1-(2,5-dimethoxy benzaldehyde)-2-aminoethanol
|
|
CN102020662A
|
|
Method for preparing torisel
|
|
CN102020661A
|
|
Method for synthesizing torisel
|
|
CN101899035A
|
|
Preparation method of high-purity imatinib
|
|
CN101891691A
|
|
Method for preparing erlotinib hydrochloride
|
|
CN101914073A
|
|
Preparation method of 5-hydroxymethylthiazole
|
|
CN101798289A
|
|
Method for preparing Erlotinib intermediate
|
|
CN101735161A
|
|
Preparation method of rizatriptan benzoate intermediate
|
|
CN101735197A
|
|
Method for synthesizing Imatinib
|
|
CN101735296A
|
|
Method for preparing fludarabine
|
